For this we treated various cancer cell lines (HCT116, DLD1, HT29 (all three colorectal adenocarcinoma), A549 (non-small-cell lung adenocarcinoma), MCF7 (breast adenocarcinoma), HeLa (cervical carcinoma), MDA-MD-468 (breast adenocarcinoma), and Saos-2 (osteosarcoma)) with a DNMT1-selective noncovalent inhibitor that does not cause DNA damage, GSK368503237. This evidence concerns the gene DNMT1 and cervical carcinoma.